The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Clomiphene citrate exposure was associated with higher rates of multiple births and perinatal adverse outcomes such as stillbirth.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...